Andrea T. Deyrup, M.D., Ph.D., has authored an article along with Joseph L. Graves, Jr., Ph.D., titled “Racial Biology and Medical Misconceptions” that was released in the February 5th  2022 issue of The New England Journal of Medicine.

Dr. Michael Datto, MD, PHD, FCAP, and Dr. Diana M. Cardona, MD, FCAP, are featured for their leadership of the Clinical Laboratories at Duke University Health System during the pandemic in the February 2022 College of American Pathologists’ Executive Briefing.

Please join us in welcoming Francis J. Sun, DVM, DACLAM, MBA, to the Department of Pathology as an Assistant Professor. 

Prostate cancer cells rely on an amino acid called glutamine to fuel their rapid growth and invasive behavior, as reported by Dr.

Pathology Chair Jiaoti Huang, M.D., Ph.D., is senior author of a groundbreaking study that identifies a molecular signal that can be developed into a test to identify patients in need prostate cancer treatment early in their diagnosis.

We are pleased to welcome Mikhail (Misha) Nikiforov, Ph.D., to Duke. Nikiforov is coming to us from the Wake Forest School of Medicine and Wake Forest Comprehensive Cancer Center, where he was Professor of Cancer Biology and co-Leader of the Cancer Genetics and Metabolism Program.

Dr. Jiaoti Huang will receive a new National Institutes of Health (NIH) RO1 grant titled “Glutaminase I Isoforms as Personalized Biomarkers of Prostate Cancer”, starting January 1, 2022. The grant will support Huang lab’s long-term research goal of discovering novel biomarkers for the optimal diagnosis and treatment of patients with prostate cancer.

Ashley Rose Scholl, M.D., MSc, PGY-1, was selected to attend USCAP’s 2022 Annual Meeting with a Pathologist-in-Training Travel Award, for her project with Dr. Rami Al-Rohil, an Assistant Professor of Pathology at Duke: MALDI Imaging Mass Spectrometry Differentiates Basal Cell Carcinoma from Trichoblastoma and Trichoepithelioma.  

The Mike Slive Foundation has awarded a grant to Qianben Wang, PhD, to develop a CRISPR/Cas13d-based therapeutic nanoparticle targeting the FOXA2 transcription factor to inhibit neuroendocrine prostate cancer metastasis.

Laura Barisoni, MD, a Duke Pathology Professor, is the leading pathologist for the Nephrotic Syndrome study Network (NEPTUNE) and principal investigator of a study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It aims to study and reframe the classification of proteinuric diseases like Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD).